Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
Open Access
- 21 December 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 12 (2), 119-127
- https://doi.org/10.1038/tpj.2010.87
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Optimally splitting cases for training and testing high dimensional classifiersBMC Medical Genomics, 2011
- A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancerBMC Cancer, 2009
- Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabineBMC Cancer, 2008
- Epidermal growth factor receptor structural alterations in gastric cancerBMC Cancer, 2008
- Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinomaBritish Journal of Cancer, 2006
- Molecular-pathological prognostic factors of gastric cancer: a reviewGastric Cancer, 2005
- Semi-Supervised Methods to Predict Patient Survival from Gene Expression DataPLoS Biology, 2004
- DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancerBiochemical and Biophysical Research Communications, 2004
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995